Managing Delirium with FLUvoxamine treatment in Non-Cardiac Surgical patients: a feasibility trial

Double-blind placebo-controlled randomised controlled feasibility trial to assess the feasibility of a larger multi-centre study. The rationale for the study are based on the known action of the drug fluvoxamine to reduce inflammation in the brain. The main objective of this pilot is to determine feasibility on a larger scale - including rate of recruitment, adherence to drug, ability to preform research activities and reporting adverse events related to the drug. As this is a pilot study our hypothesis is that more than 25% of patients approached will be happy to enrol in the study, 80% of enrolled participants will adhere to the study drug schedule and we will be able to collect measurable information on 90% of the participants. Secondary objectives include instance and severity of post-operative delirium, changes in EEG from intra-operative recording to and post-operative day 1, and collecting blood results/bio-markers associated with inflammation. Previous randomised control trials of prophylactic interventions to treat delirium have shown modest effectiveness. The intervention (Fluvoxamine 100mg oral tablet) or placebo will be administered on the evening prior to surgery, day of surgery and post-operative day one. Participants will be asked to partake in cognitive assessments, delirium assessments and have routine bloods drawn as part of daily research activities.